Introduction
============

Epidural anesthesia is widely used not only for Caesarean section but also for normal transvaginal labour and delivery.^([@B1])^ The relationship between oxidative stress and pregnancy has been widely studied, and a certain amount of reactive oxygen species (ROS) is necessary for the normal development of human embryos and fetuses, but an excess of ROS or oxidative stress may cause placental dysfunction, which may affect fetal development.^([@B2])^ Whether maternal anesthesia has any effect on the generation of placental oxidative stress is mostly unknown.

8-Hydroxy-2\'-deoxyguanosine (8-OHdG) is a frequently used marker for evaluating oxidative stress.^([@B3])^ Nuclear immunostaining can be observed in various conditions associated with oxidative stress, such as in the human epidermis in association with aging and sun-exposure and in rat hepatic ischemia-reperfusion or myocardial infarction.^([@B4]--[@B6])^ In human pregnancy, 8-OHdG staining has been observed in the placentas of pre-eclampsia patients with elevated serum uric acid,^([@B7])^ and the serum concentration of 8-OHdG has been significantly associated with prolonged labor.^([@B8])^

4-Hydroxy-2-nonenal-modified proteins (HNE) is another marker for oxidative stress.^([@B9],[@B10])^ Elevated HNE levels have been reported in the sera of type 2 diabetes mellitus patients,^([@B11])^ skin-flaps after ischemia, hepatic ischemia-reperfusion rat models,^([@B5],[@B12])^ human alcoholic liver disease,^([@B13])^ and chorioamnionitis.^([@B14])^

In this study, we performed immunohistochemical analysis to evaluate whether any correlation exists between 8-OHdG and HNE levels and the usage of epidural anesthesia in the human placenta.

Materials and Methods
=====================

Placental samples
-----------------

Placentas were obtained from 21 cases of normal transvaginal delivery (V group), 20 Caesarean sections (C group), and 17 normal transvaginal deliveries with epidural anesthesia (E group). The clinical details of the mothers and babies are summarized in Table [1](#T1){ref-type="table"}. Written permission was obtained from each mother. The ethical committees of Nagoya University Graduate School of Medicine, Bell Research Center for Reproductive Health and Cancer, and Asamoto Clinic approved the experiments. The placentas were immediately fixed with phosphate-buffered saline neutralized 10% formalin, cut within 24 h, and then further fixed for a total of 24 to 48 h. Formalin-fixed, paraffin-embedded sections were used for evaluation; they were obtained using a transverse section from the maternal to fetal surface at the intermediate area from the umbilical cord to the terminal villi of the placenta.

Immunohistochemistry
--------------------

Immunohistochemistry for the detection of 8-OHdG and HNE was performed as previously described^([@B15],[@B16])^ using primary antibody clones, N45.1^([@B3])^ and HNE-J2,^([@B9],[@B17])^ respectively. For a positive control, 6-week-old male Wistar rats were subjected to intraperitoneal injection of 15 mg of iron/kg of ferric nitrotriacetate (Fe-NTA) which was prepared immediately before use, as previously described.^([@B3],[@B9])^ The animals were sacrificed 1 h after injection. Formalin-fixed, paraffin-embedded kidney samples from Fe-NTA-treated or untreated rats were used to optimize the immunostaining procedure. Dilutions of the primary antibodies and the methods for antigen retrieval were ×2,000 and proteinase K digestion for 8-OHdG and ×10,000 and heat addition for HNE. Immunostaining was performed using a Bond-III automatic immunohistochemistry staining system (Leica, Wetzlar, Germany). Positive staining for 8-OHdG was scored using a Keyence BZ-9000 microscope (Keyence, Osaka, Japan) by automatically scoring the intensity of positive nuclear staining for 20 chorionic villi for each placenta, using a cut-off value of 70 for the signal intensity. The analysis was performed in triplicate. For HNE staining, the degree of positively stained vasculature was compared in low-magnification images from 3 sections.

Statistical analysis
--------------------

The results were analysed using analysis of variance and Student's *t* test. *P*\<0.05 was considered to be statistically significant.

Results
=======

Clinical data
-------------

The clinical data of the 3 groups are summarized in Table [1](#T1){ref-type="table"}. The durations of labor varied from 3 h 17 min to 27 h 23 min (median 10 h 55 min) in the V group and from 2 h 5 min to 16 h 55 min (median 6 h 50 min) in the E group. The ages of the mothers and the weights of the babies did not differ among the 3 groups.

Placental histology
-------------------

All of the human placentas included in this study were found to have normal term development, and none of the cases showed chorioamnionitis or tumors. The size of the placentas, number of syncytial knots, and percentage of infarcted areas did not differ among the groups. Representative results of H&E staining and immunohistochemical staining for the analysis of oxidative stress are shown in Fig. [1](#F1){ref-type="fig"}.

8-Hydroxy-2\'-deooxyguanosine (8-OHdG)
--------------------------------------

Positive 8-OHdG immunostaining was observed in the nuclei of the syncytiotrophoblasts at the surfaces of the chorionic villi of the placentas from the V group (Fig. [1](#F1){ref-type="fig"}A). In contrast, the levels of 8-OHdG immunostaining were significantly lower in the placentas from both the C group and the E group (Fig. [1](#F1){ref-type="fig"}B and C). Significant differences were observed between the V group and the C group (*p*\<0.001) and the V group and the E group (*p*\<0.001), but not between the C group and the E group (*p* = 0.792) (Fig. [2](#F2){ref-type="fig"}).

4-Hydroxy-2-noneal-modified proteins (HNE)
------------------------------------------

Positive HNE immunostaining was frequently observed in the vessel lumens in the chorionic villi in the V group (Fig. [1](#F1){ref-type="fig"}D). In contrast, the frequency of positive staining was significantly lower in the placentas from both the C group and the E group (Fig. [1](#F1){ref-type="fig"}E and F). Significant differences were observed between the V group and the C group (*p*\<0.001) and between the V group and the E group (*p*\<0.001), but not between the C group and the E group (*p* = 0.128) (Fig. [2](#F2){ref-type="fig"}).

Discussion
==========

This is the first study to report the relationship between pain-reducing anesthesia and oxidative stress in human placenta. According to a previous report, anesthesia and analgesia do not affect the health state of the newborn, as indicated by Apgar score; cord blood pH; the occurrence of hypoglycemia, hyperbilirubinemia, and respiratory depression; the lack of changes in the levels of cortisol, beta-endorphin, and two oxidative stress markers (total hydroperoxide and advanced oxidation protein products) in the cord arterial blood and extremely high levels of 2 cytokines (IL-1 beta and IL-8) in the epidural analgesia group.^([@B18])^ Although numerous previous studies have examined the association between pregnancy and oxidative stress, evidence that maternal anesthesia affects the condition of the fetus or neonate is lacking.^([@B19])^ While a certain amount of reactive oxygen species (ROS) is necessary for normal embryonic and fetal development, an excess of ROS or oxidative stress is associated with maternal obesity, smoking and hypertension. Furthermore, excess ROS affects the placental microvasculature and, therefore, has negative effects on fetal health in regards to fetal intrauterine growth retardation and maternal pre-eclampsia.^([@B2],[@B20]--[@B22])^ ROS are small molecules that can easily be transferred through maternal-fetal interfaces; thus, the presence of oxidative stress markers in the placenta should reflect maternal oxidative stress that may negatively affect the fetus. This study showed for the first time that oxidative stress is reduced by maternal anesthesia as indicated by the levels of 2 different markers of oxidative stress.

In our analysis, 8-OHdG staining was mostly observed in the nuclei of viable syncytiotrophoblasts lining the chorionic villi. 8-OHdG is a marker of oxidized DNA caused by either acute or chronic oxidative stress,^([@B23]--[@B25])^ and elevated 8-OHdG and HNE are observed in Fe-NTA-treated mouse kidneys as early as 1 h post peritoneal injection.^([@B23])^ Thus, the positive staining of these 2 markers in our study could reflect acute production of ROS that was somehow caused by the maternal condition during labor or during the surgical procedure in the case of Caesarean section. Positive staining for 8-OHdG was also observed in the endothelial cells of the vessels in the chorionic villi and apoptotic syncytiotrophoblastic cells and syncytial knots of the V group placentas. Further analyses are necessary to clarify the biological implications of these findings because positive staining in viable versus non-viable syncytiotrophoblasts may differ, and oxidative stress may cause effects that disrupt the term placenta in a manner that is not related to the maternal condition. The reason for the presence of HNE in the vessels is also unclear. HNE is typically observed in the cytoplasm of cells undergoing lipid peroxidation,^([@B15])^ but a previous report suggested that it is related to oxidized serum albumin level in diabetes mellitus patients,^([@B11])^ thus, positive HNE staining of the vessel lumens in our study may also reflect oxidation of serum proteins. Alternatively, the observed positive HNE staining may have indicated the presence of peroxidized lipids in the vasculature, and the direct target of HNE staining in this study remains unclear.

In this study, we analyzed placentas from mothers who delivered by three distinct methods: normal transvaginal delivery, Caesarean section, and normal transvaginal delivery with epidural analgesia for pain reduction. Previous studies have most commonly divided methods of delivery into 2 groups, normal transvaginal and Caesarean section, when focusing on the relationship between labor and oxidative stress.^([@B8],[@B26]--[@B28])^ With the exception of one study,^([@B26])^ oxidative stress levels have been found to be lower in Caesarean section patients,^([@B8],[@B27],[@B28])^ emphasizing that oxidative stress-induced defense systems are up-regulated during labor.^([@B8],[@B27])^ In this study, we included the E group to clarify whether labor or anesthesia contributes to changes in oxidative stress levels, and we succeeded in demonstrating that anesthesia may have positive effects on reducing oxidative stress in the term placenta for the first time. The median durations of labor in the V, E, and C groups were 10 h 55 min, 6 h 50 min, and 0 h 0 min, respectively. Therefore, we cannot exclude the possibility that a longer duration of labor contributed to higher levels of oxidative stress in the V group; however, the labor duration times in each group had no correlation with the signal intensity of 8-OHdG or the numbers of HNE-positive vessels (Fig. [3](#F3){ref-type="fig"}), and no significant difference was observed between the E and C groups, which had very different labor durations. Thus, we suggest that the observed differences in the oxidative stress markers were probably due to the administration of anesthesia to the mothers, in other words, whether the mothers experienced pain during delivery.

In conclusion, for the first time, we evaluated oxidative stress by immunostaining of human placenta for 8-OHdG and HNE following deliveries performed with or without maternal anesthesia. We successfully demonstrated that oxidative stress was significantly reduced in the placenta of mothers who delivered under epidural analgesia. Pain reduction may benefit both mothers and newborns.
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![Immunostaining results of 20 chorionic villi stained with 8-hydroxy-2\'-deoxyguanosine (8-OHdG) are shown for the V group (A), C group (B), and E group (C). Signal intensities greater than 70 are highlighted in red; this was done by the BZ9000 analysis software. Many red signals are observed in the V group compared to in the C group and E group. The results of immunostaining for 4-hydroxy-2-nonenal-modified protein (HNE) are shown for the V group (D), C group (E) and E group (F). Note that some cross sections of the vessels are positive in the chorionic villi of the V group (arrows). Hematoxylin and eosin (H&E) staining of representative sections of placentas from the V group (normal transvaginal delivery) (G), C group (Caesarean section) (H), and E group (transvaginal delivery with epidural anesthesia) (I).](jcbn15-138f1){#F1}

![(A) Signal intensity of immunopositivity for 8-hydroxy-2\'-deoxyguanosine (8-OHdG) for the V (normal transvaginal delivery), C (Caesarean section), and E (transvaginal delivery with epidural anesthesia) groups. (B) Number of positive vessels per low-magnification area identified by 4-hydroxy-2-nonenal--modified proteins (HNE) immunostaining for the 3 groups. **\*\*\****p*\<0.001.](jcbn15-138f2){#F2}

![Labor duration and oxidative stress. Labor time (h: hours) and signal intensity of immunopositivity for 8-hydroxy-2\'-deoxyguanosine (8-OHdG) for the V (normal transvaginal delivery) group (A) and E (transvaginal delivery with epidural anesthesia) group (B); number of positive vessels identified by 4-hydroxy-2-nonenal--modified protein (HNE) immunostaining for the V group (C), and E group (D).](jcbn15-138f3){#F3}

###### 

Clinical data of the 58 placentas

  Sample no.   Maternal age   Birth weight (g)   Gender of baby   Apgar score   Duration of labor (h:min)   Anesthetics                                                                                  Complication           Multipara or primi-gravida
  ------------ -------------- ------------------ ---------------- ------------- --------------------------- -------------------------------------------------------------------------------------------- ---------------------- ----------------------------
  V-1          37             3,234              male             9             9:37                        ---                                                                                          n.p.                   p
  V-2          31             3,404              male             8             22:27                       ---                                                                                          n.p.                   p
  V-3          33             2,486              female           9             3:40                        ---                                                                                          n.p.                   p
  V-4          35             2,648              female           9             7:43                        ---                                                                                          n.p.                   p
  V-5          29             3,296              male             9             4:58                        ---                                                                                          n.p.                   p
  V-6          31             3,248              male             8             12:46                       ---                                                                                          n.p.                   p
  V-7          22             2,980              female                         6:01                        ---                                                                                          n.p.                   p
  V-8          26             2,790              female           9             11:39                       ---                                                                                          n.p.                   p
  V-9          ---            ---                ---              ---           ---                         ---                                                                                          stillborn (34 weeks)   p
  V-10         27             3,128              male             9             15:33                       ---                                                                                          n.p.                   p
  V-11         35             3,040              female           9             14:09                       ---                                                                                          n.p.                   p
  V-12         24             3,048              female           9             5:12                        ---                                                                                          n.p.                   p
  V-13         24             3,082              male             9             21:43                       ---                                                                                          n.p.                   p
  V-14         33             3,034              female           9             4:20                        ---                                                                                          n.p.                   p
  V-15         28             2,682              male             9             15:10                       ---                                                                                          n.p.                   p
  V-16         35             2,880              male             9             10:12                       ---                                                                                          n.p.                   p
  V-17         30             3,284              female           9             17:45                       ---                                                                                          n.p.                   p
  V-18         35             3,484              female           9             3:17                        ---                                                                                          n.p.                   p
  V-19         24             3,246              female           9             15:50                       ---                                                                                          n.p.                   p
  V-20         29             3,130              male             10            27:30                       ---                                                                                          n.p.                   p
  V-21         31             3,480              female           9             7:15                        ---                                                                                          n.p.                   p
  C-1          30             2,942              male             9             ---                         0.5% bupivacaine 2.6 ml                                                                      n.p.                   NK
  C-2          31             3,268              male             9             ---                         propofol 100 mg, fentanyl 80 mg, pentazocine 30 mg, 1% sevoflurane 7 min, N~2~O 40l 32 min   n.p.                   NK
  C-3          30             2,960              male             9             ---                         0.5% bupivacaine 2.3 ml                                                                      n.p.                   p
  C-4          34             3,578              male             9             ---                         0.5% bupivacaine 2.5 ml                                                                      n.p.                   p
  C-5          29             3,326              male             9             ---                         0.5% bupivacaine 2.5 ml                                                                      n.p.                   p
  C-6          36             3,608              male             9             ---                         0.5% bupivacaine 2.6 ml                                                                      n.p.                   p
  C-7          25             2,536              male             9             ---                         0.5% bupivacaine 2.5 ml, fentanyl 0.4 ml                                                     n.p.                   p
  C-8          29             2,980              male             9             ---                         0.5% bupivacaine 2.5 ml                                                                      n.p.                   p
  C-9          32             3,488              male             8             ---                         0.5% bupivacaine 2.5 ml                                                                      n.p.                   p
  C-10         33             3,098              male             10            ---                         0.5% bupivacaine 2.5 ml                                                                      n.p.                   p
  C-11         36             3,310              male             8             ---                         0.5% bupivacaine 2.3 ml                                                                      n.p.                   p
  C-12         31             2,950              male             10            ---                         0.5% bupivacaine 2.5 ml                                                                      n.p.                   p
  C-13         25             2,524              male             5             ---                         0.5% bupivacaine 2.5 ml × 2                                                                  n.p.                   p
  C-14         33             3,284              female           9             ---                         0.5% bupivacaine 2.2 ml                                                                      n.p.                   p
  C-15         26             2,940              male             8             ---                         0.5% bupivacaine 2.3 ml                                                                      n.p.                   p
  C-16         31             2,818              female           8             ---                         0.5% bupivacaine 2.5 ml                                                                      n.p.                   p
  C-17         26             2,940              male             8             ---                         0.5% bupivacaine 2.2 ml                                                                      n.p.                   p
  C-18         33             3,366              male             7             ---                         0.5% bupivacaine 2.2 ml                                                                      n.p.                   p
  C-19         28             2,986              female           9             ---                         0.5% bupivacaine 2.5 ml                                                                      n.p.                   p
  C-20         27             2,706              female           10            ---                         0.5% bupivacaine 2.2 ml                                                                      n.p.                   p
  E-1          34             3,210              male             9             6:32                        0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   mu
  E-2          27             2,980              male             9             9:55                        0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   p
  E-3          25             3,040              male             8             7:16                        0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   p
  E-4          36             3,125              male             9             6:06                        0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   p
  E-5          37             3,880              male             9             12:40                       0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   mu
  E-6          28             2,770              male             9             4:20                        0.25% levobupivacaine hydorochloride 10 ml                                                   cervical cancer        p
  E-7          33             3,230              male             9             3:08                        0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   mu
  E-8          31             2,835              male             9             6:50                        0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   p
  E-9          35             3,515              male             8             6:16                        0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   p
  E-10         34             3,010              female           8             7:45                        0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   p
  E-11         28             3,030              female           9             16:55                       0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   p
  E-12         35             3,215              male             9             2:52                        0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   mu
  E-13         32             3,545              female           9             13:20                       0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   p
  E-14         35             3,265              female           9             7:07                        0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   p
  E-15         29             3,105              male             9             16:10                       0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   p
  E-16         30             3,130              female           8             2:05                        0.25% levobupivacaine hydorochloride 10 ml                                                   hyperthyroidism        mu
  E-17         28             3,050              female           8             6:16                        0.25% levobupivacaine hydorochloride 10 ml                                                   n.p.                   p

V group, normal transvaginal delivery; C group, Caeserean section group; E group, normal transvaginal delivery with anesthesia. n.p., nothing particular; p, primigravida; mu, multipara; NK, not known.
